Compare Abeona Therapeutics Inc (ABEO) vs Albertsons Companies Inc (ACI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Albertsons Companies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Albertsons Companies Inc trades at $13.98 (market cap $6.93B). The key difference: Albertsons Companies Inc is far larger — about 18.6× Abeona Therapeutics Inc's market cap, and Albertsons Companies Inc pays a 4.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ACI | |
|---|---|---|
Market Cap | $373.32M | $6.93B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $22.33 |
52-Week Low | $4.17 | $13.45 |
Enterprise Value | $228.22M | $22.02B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Albertsons Companies (ACI) trades at $14.14, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong earnings momentum with three consecutive quarterly beats, though profitability margins remain thin at 0.26% net income margin. Analyst consensus is bullish with a $18.75 price target representing 33% upside potential. Recent developments include AI-powered search enhancements and retail media partnerships driving innovation.
ACI presents a compelling value opportunity with attractive valuation metrics (P/S: 0.09, EV/EBITDA: 6.49) and consistent revenue growth, though investors face risks from declining profit margins, increasing debt levels, and competitive grocery market pressures. The technical picture remains bearish despite fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →
